Volume -12- Issue No. - 7 July 2026

Microbioz India

www.microbiozhealth.com

Healthcare Special Edition

DIAGNOSTICS WITHOUT LIMITS

THE TECHNOLOGIES TRANSFORMING MODERN CLINICAL LABORATORIES

Inside

RNI:UPENG/2017/3675

Price:100/-

Human connections

We know that quality, reliability, and trust are of paramount importance in medical technology. This is why our precision drive systems are not only used in insulin pumps, surgical robots, and prostheses, but also in implantable systems.
medical.maxongroup.com

Precision Drive Systems

maxon

Scan QR Code to visit our website

ISO 13485:2016
ICMED 13485

www.jmitra.co.in

PRESERVING HUMAN LIFE

Proud to be a
GREAT PLACE TO WORK® CERTIFIED™
For The 4th Consecutive Year.

Great Place To Work. Certified JAN 2026-JAN 2027 INDIA

Since 1969

J. Mitra & Co. Pvt. Ltd.

.....a vision to serve mankind™

- Rapid Test Kits
- Elisa Test Kits
- Blood Grouping Sera
- FIA Test Kits
- Chemiluminescence (CLIA) Test Kits
- Medical Analyzers & Instruments

E-mail: jmitra@jmitra.co.in Tel.: +91-11-471-30-300

CE FDA NSIC CERTIFIED CO. ISO 13485 Quality Management System ISO 9001:2008

YORCO®

FACTUAL LEGACY SINCE 1964

YORCO Grossing Station

EVOLVE YOUR LAB WITH ADVANCE TECHNOLOGY



- High performance airflow
- Negative pressure air curtain/air flap
- Unique top fume catchment slots
- Crucially designed
- Ease of Use
- Integral Ventilation
- UV Disinfection
- Simplified controls
- Under Table tub wash

Model: YSI-222 Ex

YORCO®

YORK SCIENTIFIC INDUSTRIES PRIVATE LIMITED

Laboratory Equipment & Instruments

+91-1204741800

www.yorco.co.in

sales@yorco.co.in

UNIMEDITREK
UNIVERSAL GUIDANCE TOWARDS A HEALTHY FUTURE

UNIMEDITREK KSHRIOM SERIES VTP 300

Finer Specimen Processing on Each Run!

Kshriom Series Fully Automated Vacuum Tissue Processor

CE | ISO 9001:2015 CERTIFIED COMPANY | ISO 13485:2016 CERTIFIED COMPANY | FDA



UPCOMING

UNIMEDITREK PRIVATE LIMITED
14 Chitra vihar, New Delhi-110092, India
Mob: +91-9810533445 | **Email:** sales@unimeditrek.com | **Website:** www.unilabequipments.com

TABLE OF CONTENTS

Ami Polymer

Enabling Healthcare

BRONZE | Top 35% ecovadis Sustainability Rating MAR 2026

Great Place To Work. Certified INDIA

PRECISION FILTRATION. RELIABLE RESULTS.

High-performance syringe filters engineered for sterile filtration, sample preparation, and analytical excellence.

Every accurate analysis begins with a clean sample. Ami Polymer Syringe Filters are designed to deliver superior particle removal, sterile filtration, and maximum sample recovery for laboratory, pharmaceutical, biotechnology, and research applications. Manufactured in ISO-certified cleanroom facilities, they ensure consistent performance and dependable results.

Why Choose Ami Polymer?

- Multiple membrane options for diverse applications
- Low protein binding & low extractables
- Maximum sample recovery with low hold-up volume
- Color-coded housing for easy membrane identification
- Sterile & non-sterile configurations available
- Precision manufactured under stringent quality standards

Why Choose Ami Polymer?

- HPLC & UHPLC mobile phase preparation
- Instrument protection from particulates
- Sterile laboratory sample filtration
- Pharmaceutical quality control
- Analytical sample clarification
- Biotechnology research
- Environmental analysis

Engineered for Accuracy.
Designed for Confidence.

Ami Polymer Syringe Filters deliver reliable filtration solutions that help laboratories achieve precise, reproducible, and contamination-free results.

www.amipolymer.com
media@amipolymer.com

Our Staff.

Corporate Office:
Microbioz India
H1/204, Vikramaditya Tower, Alaknanda Market | Kalka Ji,
New Delhi - 110019, India
Mob:- +91-9670704431 | Tel:- +91-11-44459687
Email ID : support@microbiozindia.com

Registered with Registrar of News Paper for India with RNI No: UPENG/2017/73675

Owned, Printed, Published and Edited by Jitendra Kumar Shukla, printed at Ganapathi Overseas 1/63 Bahar-e -Sahara State Janki Puram Lucknow-226021, and Published from 631/63, Surendra Nagar, Mulayam Nagar, Chinhat - Lucknow-226016, Editor, Jitendra Kumar Shukla

Editor's Word

ear Readers,
Welcome to the latest issue of Microbioz India-Healthcare and Diagnostic special edition. It's a true pleasure to have you with us once again, and we hope you find this edition as captivating and inspiring as ever.

In this issue, we're thrilled to delve into the intriguing world of **"Diagnostics Without Limits :The Technologies Transforming Modern Clinical Laboratories"** our cover story of the month. Our team has worked tirelessly to curate content that we believe will both entertain and enlighten you, from thought-provoking features to stunning visuals that capture the essence of our chosen theme.
We are excited to showcase some incredible contributors, whose expertise and creativity have graced the pages of this magazine. Their passion for digital healthcare and innovation shines through in every article, photograph, and piece of art.
Be sure to check out our special product showcase section, where you'll find latest product launches and stories. It's a testament to our commitment to providing you, our readers, with diverse and engaging content.
As always, Microbioz India is a reflection of our dedication to delivering top-quality journalism, exquisite design, and stories that resonate with you. We're immensely grateful for your continued support and readership, which drives us to keep raising the bar.
We encourage you to connect with us through our social media channels, where you can share your thoughts, feedback, and suggestions. Your voices are what inspire and guide us in our mission to bring you a magazine that truly speaks to your interests and passions.
Thank you for choosing to spend your time with us. We hope you thoroughly enjoy this issue and that it leaves you inspired, informed, and entertained.

Enjoy the read!

Kumar Jeetendra

Microbioz India.

Magazine Publishing Company

Medicall
hospital needs expo

A-Z of Your Hospital Requirements

Medicall

INDIA'S LARGEST & NO.1 HEALTHCARE EVENT & HOSPITAL NEEDS EXHIBITION

47th Edition | 2026 | JUL

FRI	SAT	SUN
24	25	26

CHENNAI

48th Edition | 2026 | OCT

FRI	SAT	SUN
2	3	4

NEW DELHI

49th Edition | 2026 | DEC

TUE	WED	THU
8	9	10

MUMBAI

For enquiries: +91 7305 789 789 | www.medicall.in | info@medicall.in

DIAGNOSTICS WITHOUT LIMITS

THE TECHNOLOGIES TRANSFORMING MODERN CLINICAL LABORATORIES

The future of diagnostics isn't about being the first to detect a disease. The future of diagnostics lies in the ability to quantify risk, facilitate customized treatment and provide answers with more speed and efficiency than anyone else.

Clinical Diagnostics in a New Age

Healthcare systems are in the middle of a major overhaul the likes of which hasn't been seen in a long time.

Clinical labs, which were once thought of as the check-box departments, are now the building blocks of the 3P's of Medicine: Precision, Predictive and Personalized. Every treatment, Every diagnosis, and Every therapeutic intervention increasingly relies on the quality and the timeliness of lab results.

The convergence of multiple technologies such as Artificial Intelligence (AI), automation, digital and virtual pathology, high-through put sequencing and cloud computing are propelling the efficiency and the clinical utility of lab diagnostics like never before.

Laboratories of the future are already a reality. They are more efficient, effective and interconnected.

Importance of Diagnostics

Health care professionals estimate that 70% of all clinical decisions are based on the results of laboratory tests. Laboratory diagnostics are critical to virtually all facets of patient care, whether it is diagnosing and managing an infectious disease, monitoring and managing chronic disease, early detection of cancer, or designing and implementing targeted therapies.

Innovation in clinical labs is being driven by a confluence of trends:

1. the growing global burden of chronic disease,
2. the demand for earlier detection of disease,
3. advances in personalized medicine,
4. increasing workloads in the laboratories,
5. the need for quicker turnaround times, and
6. digital health.

Clinical laboratories are starting to act more like intelligent diagnostic hubs than simple testing centers.

Artificial Intelligence: The Smartening of Laboratories

Laboratories are becoming more intelligent and automated, thanks to advances in Artificial Intelligence.

AI improves the efficiency of laboratory professionals by taking over laborious tasks and offering better diagnostic solutions instead of replacing them.

Examples of AI use include:

1. Automatic diagnosis for pathology slides
2. Finding abnormal blood cells
3. Finding infectious organisms
4. Quality assurance
5. Optimal function of instrument
6. Predictive maintenance
7. Smart sample distribution
8. Assistance in clinical decisions

With the addition of more diagnostic data, Machine Learning (ML) algorithms become better and help labs work smarter and faster with minimal errors.

Total Laboratory Automation

Automating tasks has become one of the largest areas of funding in clinical labs.

Currently, Total Laboratory Automation (TLA) includes the:

1. Receiving of samples
2. Identification with barcodes
3. Centrifugation
4. Aliquoting
5. Transport to analyzers
6. Loading
7. Validation
8. Storage of samples

Robotic systems have the ability to handle thousands of samples.

TLA leads to:

1. Quick sample turnaround
2. Minimal manual sample handling
3. Improved biosafety
4. Reduced costs
5. Better optimization
6. Improved workflows

Laboratory professionals can invest their time in other analytical tasks instead of repetitive manual tasks.

Molecular Diagnostics Leading Precision Medicine

Detection of disease has been revolutionized by molecular diagnostics. There is no longer a need to wait for the manifestation of a disease to know of its presence. Molecular technologies focus on changes in the cells, genes and viruses at a much lower level.

Technologies such as:

1. PCR
2. RT-PCR
3. Digital PCR
4. NGS
5. CRISPR diagnostics
6. Liquid Biopsy
7. Multiplex Molecular Panels

Determine the presence of diseases in the areas of:

1. Oncology
2. Infectious Diseases
3. Genetic Disorders
4. Prenatal Screening
5. Transplantation
6. Rare Disease
7. Pharmacogenomics

Molecular laboratories have provided the foundation for tailoring treatment options for individual patients.

Next-Generation Sequencing (NGS) has expanded its clinical applications and is no longer a technology solely used in research. With NGS, the rapid and precise analysis of DNA and RNA is possible.

Applications include:

1. Analysis of cancer mutations
2. Hereditary disease diagnosis
3. Carrier detection
4. Sequencing of the entire genome
5. Sequencing of the entire exome
6. Surveillance of microorganisms
7. Monitoring of antimicrobial resistance

NGS continues to be implemented in more hospitals around the world, thanks to the continual decline in the cost of sequencing.

Digital Pathology Redefining Diagnostic Accuracy

Pathology used to involve the viewing of glass slides through the microscope. Digital pathology involves the ultra-high resolution scanning of entire glass slides into digital images.

Benefits include:

1. Pathology consultations at a distance
2. Diagnosis aided by digital pathology and artificial intelligence
3. Rapid report generation
4. Pathology collaboration
5. Digital storage
6. Pathology education
7. Pathology workflow management

Digital pathology and artificial intelligence can assist pathology in the detection of subtle abnormalities. Point-of-Care Diagnostics Bringing the Laboratory to the Patient

Healthcare can now be conducted outside the hospital.

Point of Care Testing (POCT) can take place in:

1. Emergency departments
2. Intensive care units
3. Outpatient clinics
4. Ambulances
5. Rural healthcare centers
6. Patients' homes

Laboratory testing can now be made portable with:

1. Blood glucose
2. Cardiac markers
3. Infectious diseases
4. Coagulation
5. Blood gases
6. Pregnancy

Rapid diagnosis can enhance clinical decision making and improve the efficiency of treatment. Automation of Microbiology Laboratories Automation has been highly successful in clinical microbiology.

Modern systems can now perform:

1. Automated culture processing
2. Colony imaging
3. Microbial identification
4. Antibiotic susceptibility testing
5. Colony recognition aided by artificial intelligence

The introduction of mass spectrometry, especially MALDI-TOF, has greatly improved the speed of microbial identification, with times being reduced from days to mere hours. Rapid microbiology facilitates a faster clinical decision of treatment, and supports the efficient use of antimicrobials.

Cloud-Connected Laboratories

The digital framework being used in laboratories has greatly enhanced the interconnectedness of laboratories.

The modern LIMS and LIS streamline workflows by connecting laboratory instruments with clinicians and the hospital information systems.

The advantages of cloud technology include:

1. Remote access
2. The ability to share data
3. Real time data reporting
4. Instrument integration
5. Quality management
6. Regulatory documentation
7. Business intelligence dashboards
8. The ability to connect digitally.
9. Quality and Regulatory Compliance

Labs with advanced technologies must balance those with quality, and modern labs are using:

1. Automated quality control
2. Electronic audit trails
3. Digital documentation
4. Instrument traceability
5. ISO 15189 Standards
6. Risk based quality systems
7. Active monitoring of processes.

Tech improves productivity, and further compliance to regulations, and improves safety of patients.

Sustainability of Clinical Labs

Environmental healthcare concerns are slowly becoming more important to laboratories.

Less waste through the use of:

1. Analyzers that use less energy
2. Less use of reagents
3. Sustainable packaging
4. Water conservation

5. Smart management of supplies
6. Less waste.

Sustainability allows for long term healthcare and operational improvements.

The Lab Workforce of the Future

Automation has taken over less important processes, but skilled laboratory workers are still needed.

Laboratory scientists of the future will do more:

1. Data interpretation
2. Validation of Artificial Intelligence
3. Molecular technologies
4. Bioinformatics
5. Quality control
6. Management of digital work processes
7. Clinical practice.

Lifelong learning and the ability to work with many different fields will be the focus of the future leaders of laboratories.

The Future

Clinical laboratories will be more intelligent, more automated, more predictive, and more focused on the patient.

Novel technologies such as:

1. Diagnostics using AI
2. Biosensors
3. Digital twins
4. Advanced genomics and
5. Health monitoring that is continuous

Will transform not only the detection of disease but also the delivery of healthcare.

Digital technologies are no longer optional for these organizations. Those laboratories which embrace digital transformation, workforce development, and innovation today will have the best chances of capitalizing on the opportunities that modern medicine will bring.

Conclusion

The combination of speed, accuracy, automation, and digital connectivity will have a substantial impact on patient outcomes. Modern diagnostics are having a huge impact on the integration of technology into clinical medicine.

The combination of advanced molecular tests and digital pathology, artificial intelligence and cloud technologies, flexible and scalable, will greatly enhance the modern diagnostic process.

As this technology continues to evolve, clinical laboratories will remain the center of all medical decision-making. Clinical diagnostics will provide the evidence that enables physicians to intervene faster and ultimately transform patient care.

The laboratories of the future will not only process samples; they will be the backbone of clinical medicine and will drive the diagnostics and the future of health care.

Laboratories Powering Modern Healthcare

The Positive Effects of Advanced Diagnostics, Automation, & Digital Innovations on Patient Care

The inclusion of laboratory medicine in healthcare is continuing to expand. Rather than being relegated to processing samples on the sidelines, laboratory medicine is at the forefront of the evolution of precision medicine, disease prevention, and public health. Almost 70% of clinical decisions are based on laboratory results. This makes laboratory medicine an essential component of the healthcare delivery system.

molecular diagnostics, artificial intelligence (AI), laboratory automation, and digital pathology are examples of the tools and innovations being incorporated into clinical laboratories. These innovations are being used to provide diagnostic insights that are being relied upon more than ever before. The reliance on laboratory results is also being used to improve the outcomes of patients by better monitoring the treatment of patients and by assisting in the early detection of diseases.

The incorporation of digital innovations into healthcare is also being used to transform laboratories into smart diagnostic centers.

The Modern Role of Clinical Laboratories

Laboratories provide critical insight into almost every aspect of patient care. This can include everything from the diagnosis of an infectious disease, the determination of a cancer biomarker, or the evaluation of a chronic disease.

The majority of modern medicine relies upon the information provided by a clinical laboratory.

1. Therapeutic drug monitoring.
2. Infection control.
3. Preventive healthcare screening.
4. Public health surveillance.
5. Precision oncology.
6. Organ transplantation support.

During laboratory medicine's critical response to the testing demands of the COVID-19 pandemic, it also showed the importance of laboratory medicine to the healthcare delivery system.

1. Automation and Its Impact on Modern Laboratories
2. Automation is changing the landscape of healthcare laboratories.

The majority of routine tasks are now handled by automated systems. These tasks include:

1. Sample reception
2. Barcode reading
3. Centrifugation
4. Aliquot preparation
5. Specimen transport
6. High-throughput testing
7. Results validation

Automation makes tasks easier and improves the speed and accuracy of lab testing.

Newer iterations of Total Laboratory Automation (TLA) are able to incorporate and streamline most of the laboratory disciplines including:

1. Clinical chemistry
2. Immunoassays
3. Hematology
4. Coagulation
5. Microbiology

Benefits of TLA systems include:

1. Increased Efficiency
2. Reliability
3. Lower Costs
4. Greater Safety

The Role of Artificial Intelligence in Healthcare Laboratories

AI is the future of laboratory medicine and is already helping many healthcare professionals. Now that laboratory professionals have the ability to delegate the review of large sets of data, they are able to focus on more important and complex tasks.

AI has already been adopted for use in:

1. Monitoring digital pathology
2. Blood smear reviews
3. Cancer screenings
4. Predictive analytics
5. Quality control
6. Optimization of laboratory workflows
7. Predicting instrument maintenance

AI should be viewed as a productivity booster that will help laboratory professionals offer diagnostic services with greater confidence. Molecular Diagnostics and Their Role in Treatment

Molecular diagnostics are changing the detection and treatment of diseases.

Some of these technologies include:

1. PCR
2. Real-Time PCR
3. Digital PCR
4. Next Generation Sequencing (NGS)
5. CRISPR diagnostics

They can now help healthcare professionals much earlier than they have been able to help with the clinical symptoms that will eventually progress to help them.

These technologies can be used to help clinicians with:

1. Detection of infectious diseases
2. Cancer diagnostics
3. Detection of rare diseases
4. Prenatal diagnostics
5. Pharmacogenomics
6. Companion diagnostics

This technology allows clinicians to target treatments to a patient much more effectively and avoid wasteful treatments.

Digital Pathology Is Changing How Diagnoses Are Made

Digitization of glass microscope slides is now a thing of the past.

Digital pathology allows pathologists to:

1. Examine slides from anywhere
2. Work with specialists from any country

3. Leverage AI for image analysis
4. Digitally store case files
5. Diagnose with more consistency

Telepathology is especially useful for hospitals that may not have easy access to the specialist expertise that they require due to the location of the hospital.

For digital pathology, the telepathology model helps speed up cancer diagnosis by making the case flow more efficient and providing support for multidisciplinary care teams.

Diagnostic Laboratories Are Moving Closer to Patients

Healthcare continues to move away from centralized laboratories.

With the advent of Point-of-Care Testing (POCT), diagnostic tests can now be performed in:

1. Emergency departments
2. Intensive Care Units
3. Operating Rooms
4. Physician Clinics
5. Ambulances
6. Community Clinics
7. Patients' Homes

The immediacy of the test result allows the clinician to make a treatment decision without delay and helps save valuable time and even patients' lives.

Examples of POCT include:

1. Blood glucose
2. Cardiac biomarkers
3. COVID-19
4. Influenza
5. Urine pregnancy
6. Blood gas

As POCT technology continues to advance, the integration of POCT into routine healthcare will be the norm.

Digital Connectivity Is Creating Smart Labs

Modern laboratories create large amounts of diagnostic data every day.

Digital systems like LIMS and LIS assist laboratories in the effective management of large amounts of data.

Connected laboratory ecosystems make possible:

1. Automated result reporting
2. EMR integration
3. Instrument connectivity
4. Quality management
5. Regulatory compliance
6. Remote monitoring
7. Data analytics

Cloud computing and cybersecurity have made secure collaboration possible across multiple hospitals and diagnostic and research laboratories.

Quality and Accreditation of Services and Products

New technology must include the highest level of quality.

ISO 15189 involves several criteria to guarantee accuracy and safety in patient results, including calibrating tools, assessing employee skills, and incorporating internal and external measures and controls for quality assurance programs. Continuous quality improvement focuses on sustaining trust in lab results.

Sustainability Is Prioritized

Establishments consume significant resources. Some laboratory practices reduce the consumption of:

1. Water
2. Chemicals
3. Energy
4. Laboratory plastic

Some examples of sustainability practices include:

1. Waste reduction plastic
2. Managing laboratory stock
3. Using laboratory chemical reagents
4. Choosing design
5. Reducing energy-consumption
6. Applying digital documents
7. Green laboratories

Sustainable laboratories help the environment and reduce costs of operating a laboratory. Sustainable laboratories help reduce the negative costs of operating a laboratory while reducing the negative impact on the environment.

Laboratory Problems in the Present

Laboratories have many issues even with the advanced technologies since the introduction of technologies to laboratories.

Some issues present are:

1. Costs to operate a laboratory are increasing
2. Not enough workers
3. More tests are being ordered
4. Cyber concerns
5. Laboratory regulations
6. Managing data workloads

How to connect platforms with other technologies

To solve these issues the focus must be on developing the technology, workers, and the infrastructure along with innovative practices.

Smart Laboratories of Tomorrow

The laboratories of tomorrow will focus on the patient and will be even smarter.

Some of the technologies that will be used are:

1. Laboratories that operate on their own with robotics
2. AI to help with diagnostics
3. Laboratories that optimize themselves digitally
4. Diagnostics that encompass all omics
5. Biosensors that are wearable
6. Laboratories and patients connected in a digital Cloud
7. Laboratories will be able to monitor patients continuously
8. Laboratories will be able to see and manage healthcare records through Blockchain
9. Laboratories will be able to integrate real-time diagnostics in a secure digital Cloud
10. Laboratories will be able to measure and evaluate patient diagnostics from anywhere at any time

Laboratories have the potential to move in the direction of not just helping to prevent the diagnosis of a disease but to also help to prevent the negative impacts to the patients from risk to their health.

Conclusion

Clinical laboratories today are essential healthcare partners that shape every aspect of the patient experience. Modern laboratories are capable of faster, more precise diagnoses that lead to improved outcomes and are the product of many of the advances in automation, artificial intelligence (AI), molecular diagnostics, digital pathology, and integrated, connected lab networks.

The data-driven, personalized future of healthcare will rely on laboratories for continued progress and innovation. Laboratories will integrate and connect the various scientific and medical disciplines to provide critical insights that continue to improve and save patient lives. Future laboratories will be more than diagnostic services.



Fighting the Obesity Crisis

*Attributed to **Dr. Rameez Raja B**, Consultant Endocrinologist, Kauvery Hospital, Radial Road*

We all know obesity is a growing problem. But here's what most people don't realize: in India, it's showing up in bodies that don't even look "obese." Patients walk into the clinic looking perfectly normal-weight, and yet they're already dealing with diabetes, fatty liver, or early heart disease. So, what's actually going on?

The Indian Twist: Why BMI Lies
Globally, obesity is measured by BMI. But Indians tend to store fat differently — more of it packed around the abdomen, liver, and pancreas, even at a BMI that looks "normal" on paper. Doctors call this the thin-fat phenotype.

Why this matters:

1. A slim-looking patient can already be at high metabolic risk
2. Waist circumference and body composition analysis catch what BMI misses
3. Type 2 diabetes, fatty liver, and early cardiovascular risk are now showing up in patients in their 20s and 30s.

Pro Tip: Don't wait for the scale to climb before checking your metabolic health.

Ask your doctor about waist circumference and basic metabolic screening, especially if diabetes or heart disease runs in your family.

The medicines changing the game:
The biggest recent shift in obesity treatment has been pharmacological.

GLP-1 receptor agonists, such as semaglutide, and dual **GIP/GLP-1 receptor** agonists, such as tirzepatide, work by mimicking gut hormones that regulate appetite and promote feelings of fullness.

These medicines are delivering results that are approaching what was previously possible only with bariatric surgery.

But there's a catch: used carelessly, these medicines can cause patients to lose muscle along with fat - a real concern for a population already prone to low muscle mass. The smart approach pairs the medicine with enough protein intake and resistance training, plus a clear long-term plan, rather than treating the injection as a stand-alone fix.

Key takeaway: These drugs are powerful tools, not magic bullets. They work best alongside nutrition and strength training - not instead of them.

Prevention still wins:
For all the excitement about new medicines, prevention remains the strongest weapon we have - and it needs to start earlier than most people think.

Sedentary urban lifestyles, processed food, excessive stress and poor sleep are quietly setting up obesity years before it shows up on a scale.

What actually helps:

1. **Protein and fibre rich meals** - especially important for vegetarian Indian diets that often lean heavy on carbs
2. **Resistance training**, not just cardio, to protect muscle as weight comes off
3. **Prioritising adequate sleep and effective stress management** is equally important, as chronic sleep deprivation and persistent psychological stress promote insulin resistance, disrupt appetite-regulating hormones, increase cravings for calorie-dense foods, and contribute to weight gain independent of dietary intake.
4. **Early metabolic screening** - don't wait until BMI crosses a threshold to check glucose, lipids, and waist circumference.

Changing the conversation:

1. Maybe the biggest shift needed isn't medical at all - it's cultural. Obesity is still too often seen as a matter of willpower, which keeps people from seeking help until complications have already set in.
2. **Don't forget:** Obesity is a chronic relapsing disease with hormonal, genetic, and environmental drivers - not a personal failure. Reframing it this way changes how early people seek treatment, and how effectively they manage it.

Final takeaways:

The obesity Crisis won't be Solved by a single injection or diet trend. I takes a Combination of modern Pharmacology, the fundamentals of nutrition and movement, and early Screening - tailored to how obesity actually shows up in Indian bodies. The sooner we treat it seriously, the less ground we lose before the scale tips into crisis.

About author:

Dr Rameez Raja B is a highly skilled endocrinologist with extensive expertise in diagnosing and managing a wide spectrum of endocrine disorders.

His areas of focus include diabetes, obesity, thyroid and parathyroid conditions, pituitary and adrenal disorders, bone health, osteoporosis, growth and pubertal concerns, as well as reproductive endocrinology, including male and female hypogonadism, male infertility, and PCOS.

He is also experienced in handling paediatric and transgender endocrinology, offering comprehensive and inclusive care for diverse patient needs.

With proficiency in both outpatient and inpatient management, including critical care support, he is known for his evidence-based approach, precise diagnosis, and patient-centric care.

His commitment to improving the quality of life through early detection, prevention, and personalised treatment strategies makes him a trusted specialist in his field.

What Syringe Filters Do—and Why They Matter

Syringe filters may appear to be simple components, but they play an important role in ensuring product quality and patient safety. Whether used in pharmaceutical manufacturing, laboratory testing, or sterile compounding, they provide the final level of filtration before a sample is analysed or a solution is administered.

A properly selected syringe filter removes particles, microorganisms, and other unwanted contaminants from liquids or gases. This not only improves the quality of the final product but also protects sensitive analytical instruments from damage and helps generate accurate, reproducible test results.

Although syringe filters are relatively small and inexpensive, selecting the right filter is critical. Choosing an unsuitable membrane or housing material can affect filtration performance, reduce sample recovery, or introduce extractable that may interfere with analytical results or product stability.

Choosing the Right Membrane

The membrane is the heart of the syringe filter, and the right choice depends on the application.

- **PES (Polyether sulfone)** is widely used for aqueous solutions because of its high flow rate and low protein binding.
- **PTFE (Polytetrafluoroethylene)** is suitable for organic solvents and gas filtration due to its excellent chemical resistance.
- **PVDF (Polyvinylidene Fluoride)** is preferred for biological samples because of its low extractable profile and broad compatibility.
- **Nylon** is commonly used for HPLC sample preparation and general laboratory filtration.

Selecting the correct membrane helps ensure optimum flow, sample compatibility, and reliable analytical performance.

Reliable Housing for Consistent Performance

The filter housing is equally important. Typically manufactured from medical-grade polypropylene, it must withstand filtration pressure while maintaining chemical compatibility and structural integrity.

Modern syringe filters are expected to comply with international standards such as USP Class VI and ISO 10993, providing confidence in biocompatibility and minimizing the risk of extractable and leachable.

Changing Market Requirements

The demand for syringe filters continues to grow as pharmaceutical manufacturing and laboratory testing become more advanced.

The increasing use of home infusion therapies requires reliable filtration products that are easy to use outside hospital settings. Growing production of generic injectable drugs has increased the need for high-quality filtration solutions supported by proper technical documentation.

At the same time, the rapid expansion of biologics and specialty pharmaceuticals has made consistent filtration even more critical because of the high value of these products.

Regulatory agencies are also placing greater emphasis on material safety, traceability, and documentation. As a result, customers now expect more than filtration performance—they expect complete technical support and compliance with global quality standards.

Why Choose Ami Polymer

Ami Polymer combines advanced polymer processing expertise with precision manufacturing to deliver reliable syringe filters for laboratory and pharmaceutical applications.

Manufacturing is carried out in controlled cleanroom facilities following internationally recognized quality systems, including **ISO 13485:2016**, **ISO 9001**, **US FDA registration**, **USP Class VI**, and **ISO 10993** compliance. Every product is designed to provide consistent pore size, secure membrane bonding, and reliable luer connections for dependable performance. With extensive experience in medical-grade silicone and polymer products, OEM manufacturing capabilities, and a European warehouse that supports faster deliveries, Ami Polymer is a trusted partner for customers seeking high-quality filtration solutions backed by technical expertise and dependable service.

Conclusion

Syringe filters are a small but essential part of laboratory and pharmaceutical workflows. Their role extends beyond simple filtration—they help maintain sample integrity, protect valuable equipment, and support accurate analytical results. As quality expectations and regulatory requirements continue to increase, choosing a reliable manufacturing partner becomes just as important as selecting the right filter itself. Ami Polymer is committed to delivering high-performance syringe filters that combine quality, consistency, and regulatory compliance for customers worldwide.

Author: Divya Joshi
Executive Domestic Marketing
divya.j@amipolymer.com



LVPEI Redesignated WHO Collaborating Centre for the Prevention of Blindness

The World **Health Organization** (WHO) has redesignated **L V Prasad Eye Institute** as a Collaborating Centre for the **Prevention of Blindness** for a period of 4 years (till 2030). LVPEI first achieved this designation twenty-five years ago, in 2001. LVPEI is one of 11 eye care institutions designated by the WHO Director General to support WHO's global eye care and blindness prevention programs.

LVPEI
So that all may see
LV Prasad Eye Institute

Nearly 2.2 billion live with some form of vision loss in the world. It is estimated that about half that number—nearly 1 billion people—have never received eye care. Most of them live in middle- and low-income countries. Some two-thirds of those who need glasses, don't have access to them, and only 1 out of 2 people who need cataract surgery receive the procedure.

The WHO collaborating centres are a multilateral network of high-quality eye care institutions that support the WHO in addressing these gaps and making integrated, people-centred eye care a reality.

As a WHO Collaborating Centre, LVPEI will support the United Nations (UN) body's goal of achieving universal health coverage with its technical and operational expertise. LVPEI's large pyramidal network and expertise in public health epidemiology will help generate evidence for best practices, train an adequate eye health workforce, and develop eye health guidelines.

A key area of expertise will be LVPEI's experience in taking eye care to rural areas. A key aspect of universal health coverage will be ensuring that eye care is available to those who are underserved.

"This redesignation underscores two decades of collaboration between LVPEI and WHO in taking public health eye care forward," noted **Dr Gullapalli N. Rao**, Founder Chair, LVPEI. "It is an honor and a responsibility. The burden of vision loss is highest in our settings—but so are the diversity of solutions. We look forward to making a difference in the coming years," he said.

"The WHO Collaborating Centre designation includes a detailed work plan and the need for technical inputs into global eye care strategy for the next four years. I am confident that, in partnership with our colleagues in the WHO, we will be able to achieve our targets." said **Dr Rohit Khanna**, Network Director--Public Health, LVPEI.

Editor's Notes:

What is a WHO (World Health Organization) Collaborating Centre?

"A collaborating centre is defined as an institution officially designated by the WHO Director-General to support WHO programmes at national, regional, inter-regional and global levels."

These WHO collaborating centres came about based on the policy adopted at the Second World Health Assembly in 1949 by the League of Nations that WHO would only support, coordinate and use the work of existing institutions around the world and not establish any research institutes of its own.

The collaborating centres reinforce national health capacity by contributing information, services, research and training to support improvements in public health. They help with gathering, analyzing, and sharing data; standardizing terminology, technology, diagnostics and therapeutics; provide reference materials; participate in collaborative research under WHO leadership; provide training; and coordinate work conducted by multiple institutions on specific topics.

These collaborations ensure the scientific credibility of global health initiatives and strengthen WHO's leadership role in shaping the International Health Agenda.

About LVPEI: Established in 1987, with the vision, 'to create excellent and equitable eye care systems that reach all those in need,' the L V Prasad Eye Institute (LVPEI), a comprehensive eye health facility, is a World Health Organization Collaborating Centre for the Prevention of Blindness.

In pursuance of this vision, LVPEI clinician scientists work at the cutting edge of eye research. Through its five-tier 'Eye Health Pyramid' and cross-subsidy models, LVPEI provides more than 50% of its services entirely at no cost to the patient, irrespective of the complexity of care needed. LVPEI is among the world's top eye researchers with over 5,000 published scientific papers in prominent international journals.

Psychiatric Social Counselors to assist patients at Institute of Mental Health (IMH)

· *17 Patients reunited with the families after successful counselling in the last 30 days*

A team of qualified and well-trained Psychiatric Social counselors will be assisting patients **Institute of Mental Health (IMH)** – Eragadda, the state-run tertiary center for mental Health.

Helping Hand Foundation, the health care nonprofit that provides voluntary patient care support services and systems in state run hospitals has now collaborated with **IMH** to enhance patient care & counseling services.

The Counseling services are mapped in the **Discharge Ward (DC Ward)** where the patients who have completed treatment & are mentally stable but yet to be taken back by their families, the **de-addiction ward & the Clinical Psychology department**, apart from the In-Patient wards, counselors will assist patients in the **OPD Block** and in the pharmacy block.

A total of **5** Psychiatric Social workers, **2** in DC Ward and de-addiction ward, **1** in Clinical Psychology ward and **2** in OPD have been assigned the duty as per the roster issued by the hospital.

The main task of Counselors in the **DC & de addiction ward** will be to enhance family support, communication and patient social engagement. The counselors are tasked to have daily interactions with the family members to help reconnect the patients back to the family, since the launch of the counselling services **17** patients have been successfully rejoined with their families.

Apart from this, the counselors are engaging in helping them do yoga, stretching, and breathing exercises. There is a library area where they read newspapers and books, practice writing etc. Cognitive behavioral activities, brain games, recreational therapy along with motivational sessions are some of the other activities which the counselors are helping the patients perform.

In addition to the helpdesk services, HHF has also contributed towards improving patient welfare by providing **50** plastic chairs, indoor games, wall fans, a large screen LED TV and by undertaking civil works, wall painting in the female ward, toilet renovation works and other infrastructure improvements.

The Counselors services at IMH were formally inaugurated by **Dr. K. Shiva Prasad,** Superintendent IMH, in presence of Senior RMOs and staff of the hospital on 1st July 2026.

Livasa Hospitals Strengthens Digital Transformation Journey with the Appointment of Bhoopendra Solanki as Chief Information Officer

As healthcare rapidly evolves through digital technologies, artificial intelligence and connected care, hospitals are increasingly investing in technology to enhance clinical outcomes, improve patient safety and deliver seamless care experiences. Reinforcing its commitment to building a future-ready healthcare network, Livasa Hospitals has appointed Mr. Bhoopendra Solanki as its Chief Information Officer (CIO).

Mr. Anurag Yadav, CEO, Livasa Hospitals along with Mr. Bhoopendra Solanki, CIO, Livasa Hospitals

The appointment comes at a significant stage in Livasa Hospitals' growth journey as the network expands its regional footprint across North India while strengthening its digital capabilities.

With technology becoming central to every aspect of healthcare-from diagnostics and clinical decision-making to patient engagement, cybersecurity and hospital operations, Livasa is making strategic investments to build an integrated, intelligent and patient-centric healthcare ecosystem.

Livasa
We care for life

An alumnus of IIM Calcutta, Mr. Solanki brings over 25 years of experience in healthcare information technology and digital transformation. He has held senior technology leadership positions at Sakra World Hospital, Kokilaben Dhirubhai Ambani Hospital, Medanta – The Medicity and Fortis Healthcare Ltd.

Over the course of his career, he has successfully led enterprise-wide digital transformation across multi-hospital networks and greenfield healthcare projects. His expertise spans Hospital Information Systems (HIS), PACS, ERP, SAP S/4HANA, cloud infrastructure, cybersecurity, CRM platforms, Artificial Intelligence (AI), Machine Learning (ML), Robotic Process Automation (RPA), Internet of Things (IoT), data analytics and digital patient engagement platforms.

He has also led the implementation of Electronic Medical Records (EMR/EHR), Patient and Doctor Mobile Applications, Patient Portals, Telemedicine and Remote Care solutions, helping healthcare organisations improve efficiency, strengthen clinical workflows and enhance patient experience. Mr. Solanki is also an author and thought leader, contributing to discussions on healthcare technology and digital innovation.

Welcoming him to Livasa Hospitals, **Mr. Anurag Yadav, Chief Executive Officer, Livasa Hospitals**, said, "*Healthcare is undergoing one of its biggest transformations, with technology becoming a critical enabler of better clinical outcomes, safer care and enhanced patient experience. As Livasa Hospitals continues its growth journey, building a robust digital ecosystem is a strategic priority for us.*

Bhoopendra's rich experience in leading technology transformation across some of India's premier healthcare institutions will help us accelerate this journey and create an integrated, secure and future-ready healthcare network."

As Chief Information Officer, Mr. Solanki will lead Livasa Hospitals' enterprise technology strategy and digital transformation roadmap. He will oversee the development of an integrated technology ecosystem across the network, with a focus on strengthening IT infrastructure, cybersecurity, data governance, AI-led innovation, automation and digital platforms that improve operational efficiency, clinical outcomes and patient engagement.

His appointment reflects Livasa Hospitals' continued investment in leadership, innovation and technology as the Group expands its regional footprint and advances its vision of delivering world-class healthcare closer to the communities it serves.

About Livasa Hospitals
Livasa Hospitals is one of North India's leading healthcare networks, committed to delivering advanced, accessible, and patient-centric medical care. Backed by IndiaRF, network has over 950 beds, supported by 250+ doctors and 40+ super-specialties, across Mohali, Amritsar, Hoshiarpur, Nawanshahr, Khanna, with further expansion underway across the region. Livasa Hospitals offers comprehensive tertiary and quaternary care services across Cardiac Sciences, Neurosciences, Oncology, Orthopaedics, Renal Sciences, Critical Care, Gastro Sciences, Mother & Child Care, Emergency Medicine, and several other specialties.

Guided by a commitment to clinical excellence, innovation, and compassionate care, Livasa Hospitals continues to strengthen healthcare access and improve health outcomes for communities across North India.

Sankara Eye Hospitals Successfully Hosts 20th Annual VISION 2020 India Conference, Celebrating 50 Years of the Sankara Movement

Sankara Eye Hospitals, in association with VISION 2020 India, successfully concluded the 20th Annual VISION 2020 India Conference held from 10 to 12 July in Bengaluru. The conference brought together leading ophthalmologists, optometrists, public health experts, policymakers, researchers, development partners and healthcare professionals from across the country to deliberate on the future of eye care in India.

From Left to Right - Dr Shalinder Sabherwal, Dr Rupali Chopra, Dr Rajesh Saini, Krishnamachari Srikkanth, Dr R V Ramani, Peter Holland, Heidi Chase

Held under the theme "**Innovation, Collaboration and Impact in Eye Care – VISION for Viksit Bharat 2047**," the three-day conference served as a national platform for knowledge exchange, showcasing innovations and strengthening partnerships aimed at eliminating avoidable blindness while advancing equitable, accessible and high-quality eye care across India.

Inauguration of Vision 2020

The scientific programme featured discussions across five thematic tracks: Innovations and Technological Solutions in Eye Care; Collaboration for Universal Eye Health; Impact, Equity, Sustainability and Quality in Eye Care; Excellence in Optometry and Allied Ophthalmic Personnel; and Sharing Knowledge Repository: Towards Organizational Excellence and Growth. These sessions highlighted emerging technologies, digital health innovations, collaborative healthcare models, quality improvement initiatives and workforce development strategies.

A special leadership session chaired by Dr. Rajesh Saini featured distinguished speakers including Dr. R. V. Ramani, Peter Holland, and Heidi Chase. Former Indian cricket captain Krishnamachari Srikkanth delivered an engaging session on Leadership Lessons from Cricket, drawing parallels between leadership in sports and healthcare.

Krishnamachari Srikkanth, former Indian cricket captain and Goodwill Ambassador of VISION 2020: The Right to Sight India said, " *VISION and eyesight are*

fundamental to everything we do, whether it is reading, writing, studying or playing sports. I am proud to be associated with VISION 2020 as its Goodwill Ambassador and support its efforts towards eliminating avoidable blindness in India.

Cricket has taught me that self-belief, teamwork, innovation and hard work can help achieve even the biggest goals, and with eye care professionals from across the country coming together, I believe the VISION of a blindness-free India by 2047 can become a reality."

Coinciding with the 50th anniversary of the Sankara movement, the conference marked a significant milestone in India's community eye care journey. The event celebrated Sankara Eye Foundation India's five decades of service in delivering quality eye care to underserved communities through innovation, outreach and sustainable service models.

Peter Holland, CEO OF International Agency of The Prevention of Blindness (IAPB) said, "*Eye health has evolved beyond being solely a healthcare concern to become a critical global development and economic priority, directly influencing education, employment, productivity and community participation. Strong leadership, collaboration and a unified voice across the eye care sector are essential to eliminating avoidable sight loss and advancing universal access to eye care. India's experience, innovation and commitment can play a pivotal role in shaping global action and strengthening international efforts to ensure VISION for all.*"

The conference featured keynote addresses, plenary sessions, panel discussions, scientific paper presentations, workshops and interactive sessions. Experts deliberated on artificial intelligence, digital health, community ophthalmology, public-private partnerships, quality improvement and capacity building to strengthen India's eye care ecosystem.

Dr RV Ramani, Padmashree Awardee and Founder and Managing Trustee, Sankara Eye Foundation about said, "*Viksit Bharat is not merely a government programme but a national movement that requires collective leadership across healthcare, education, industry and civil society. Healthy citizens, skilled youth, inclusive growth and sustainable institutions will be central to India's journey towards becoming a developed nation. By restoring sight, preventing avoidable blindness and strengthening healthcare capacity, eye care institutions have a vital role in ensuring that every citizen can learn, work and live with dignity. As Sankara enters its golden jubilee year after completing 3.3 million free eye surgeries, our next 50 years must demonstrate what collective leadership, compassion and sustainability can accomplish together.*"

The conference also reaffirmed the importance of collaborative action among government agencies, healthcare institutions, academia, civil society, industry and development partners in achieving universal eye health and supporting the VISION of Viksit Bharat 2047.

Speaking at the conference **Dr Rajesh Saini, President of VISION 2020** said, "*The Right to Sight India brings together over 210 organisations, with its members contributing to nearly 50–60% of the one crore eye surgeries performed in India last year. Through this conference, we aim to strengthen our collective commitment to delivering accessible, quality eye care for every citizen and contribute to the VISION of Viksit Bharat 2047.*"

The 20th edition of the conference attracted hundreds of delegates from across the country and concluded with renewed commitments towards innovation, collaboration and evidence-based approaches to strengthen India's eye care ecosystem and accelerate progress towards eliminating avoidable blindness.

Mr. Gokul V Subramaniam, President, Intel India, said, "*While India has made remarkable progress through digital transformation and public welfare initiatives, bridging the gaps in agriculture, education and healthcare requires collective action, innovation and empathy. Technology can accelerate development, but wisdom comes from character, compassion and a shared responsibility towards the most marginalized. Sankara Eye Foundation exemplifies this spirit by proving that service, sustainability and purpose-driven leadership can transform lives and inspire nation-building.*"

About Sankara Eye Foundation
Sankara Eye Foundation India is a Not-for-Profit organization committed to providing quality eye care services to the poor and marginalised sections of society.
Started as a small primary health care centre in the year 1977 by Dr R.V. Ramani and Dr Radha Ramani, today Sankara is one of the largest and fastest growing social enterprises managing 14 super speciality eye care hospitals in more than 10 states. The network hospitals are equipped with state-of-the-art technology to perform advanced eye surgeries. Sankara Eye Foundation India is a protagonist of the National Eye Health Care Movement in India, continuously transforming the eye care delivery structure through various Eye Care Initiatives across age groups, cutting-edge technology, scientific approach, innovation, research & training.

Manipal Health Enterprises Limited gets SEBI nod for its IPO

Bangalore-based Manipal Health Enterprises gets final Sebi nod for its IPO.

The Company had filed its IPO papers with Sebi on 25 March, 2026.

The IPO is a fresh issue of up to Rs 8,000 crore, and an offer-for-sale of up to 43,227,668 equity shares by promoters - Imperius Healthcare Investments Pte. Ltd, and Manipal Education and Medical Group India Private Limited. Investors selling shares include TPG SG Magazine Pte. Ltd, Seventy Second Investment Company LLC, Ammar Sdn Bhd, Novo Holdings Invest Asia A/S and Phoenix Bear Investments, LLC.

The proceeds from its fresh issuance worth Rs 5,378 crore will be utilised for repayment/ prepayment, in full or in part, of certain outstanding borrowings and accrued interest thereon availed by one of the company's material subsidiaries, Manipal Hospitals Private Limited, Rs 574 crore for acquisition of minority stake in the company's step-down subsidiary, Sahyadri Hospitals Private Limited, and general corporate purposes.

The company, in consultation with the book-running lead managers, may consider a pre-IPO Placement for up to Rs 1,600 crore. The pre-IPO placement if completed, the fresh issue size will be reduced.

About the company

The company operates a pan India network of multispecialty hospitals delivering a comprehensive range of care services, from outpatient services to complex tertiary and quaternary interventions. As of September 30, 2025, the company operates 38 hospitals (48 hospitals on a pro forma basis) with 10,761 licensed beds (12,367 licensed beds on a pro forma basis) across 14 states and union territories. It has the widest footprint in terms of presence of hospitals among private hospital chains in India as of September 30, 2025 (Source - CRISIL Report).
The company is the largest pan-India multispecialty hospital network by bed capacity and the second-largest hospital chain by number of hospitals as of September 30, 2025 (Source - CRISIL Report).
In November 2025, the company commenced operations at its 49th hospital in Bengaluru, which increased its licensed bed capacity to 12,631 licensed beds as of December 31, 2025. For Fiscal 2025, the company reported the second-highest revenue from operations of ₹92,635.56 million (on a pro forma basis) among private hospital chains in India and reported the third-highest revenue from operations of ₹82,422.50 million, among private hospital chains in India (Source - CRISIL Report).

India's No. 1 Trade Fair for **Hospitals, Health Centres and Clinics**

MEDICAL FAIR INDIA

29–31 JAN. 2026
Hall 4 & 5
Bharat Mandapam (Pragati Maidan)
New Delhi, India

17–19 SEPT. 2026
Hall 4
Bombay Exhibition Center
Goregaon (E), Mumbai, India

INTERNATIONAL EXHIBITION AND CONFERENCE

Exhibitor Profile

- Medical Equipment & Devices
- Medical Technology, Healthcare IT Systems & Solutions
- Hospital & Healthcare Infrastructure
- Pharmacy, Dispensary Equipments and Furniture
- Disposables & Consumer Goods
- Imaging & Diagnostics
- Laboratory, Analytical Equipments and Products
- Measuring & Testing Equipments
- Life Sciences and Biotechnology
- Rehabilitation, Orthopaedics & Physiotherapy
- Components

VISITOR REGISTRATION FOR DELHI EDITION

(18+ TRADE & BUSINESS VISITORS ONLY)

Special Features

AiMeD - Make In India Pavilion

Clin Lab / IVD Pavilion & Conference

Rehabilitation Pavilion

LIMITED SPACE LEFT

Future for Health Digital Health Start-up Pavilion & Conference

MT India Healthcare Awards

International Conferences

Exhibiting Countries

(Delhi Edition)

CHINA, CZECH REPUBLIC, GERMANY, INDIA, JAPAN, MALAYSIA, NETHERLANDS, SINGAPORE, SOUTH KOREA, TAIWAN, THAILAND, UK, USA

For more information, please contact: VermaA@md-india.com or 91-124-4544 **507**

An initiative by: MEDICARE ASIA

Supported by

Official Landing Pad Partner: City of Düsseldorf Economic Development

Badge Partner

Media Partner: Microbioz India

Messe Düsseldorf India

Aster Quality Care Begins Operations with a Mission to Expand Advanced Healthcare Beyond India's Metros

Operations to begin with 39 hospitals across 28 cities, with a focus on expanding specialist care, advanced treatment and medical technology beyond the metros

Aster DM Quality Care Limited today commenced operations following the successful completion of the merger between Aster DM Healthcare and Quality Care India Limited (QCIL), bringing together four trusted healthcare brands - Aster DM, CARE Hospitals, Evercare and KIMSHEALTH. More than the combination of two leading healthcare organisations, the merger creates a stronger platform with a shared purpose: expanding access to world-class healthcare by bringing specialist expertise, advanced treatment and cutting-edge medical technology closer to patients across India. In the new combined entity, Dr. Azad Moopen will continue as Executive Chairman and Mr. Varun Khanna will lead the business as Managing Director and Group CEO.

Dr. Azad Moopen, Executive Chairman & Mr. Varun Khanna, MD and Group CEO - Aster DM Quality Care Ltd

With a strong footprint across South and Central India, Aster DM Quality Care will have a significant presence in several underpenetrated fast-growing healthcare centres beyond the metros. These centres will play an increasingly important role in the group's long-term strategy to decentralise affordable and advanced healthcare by expanding specialist services, investing in cutting-edge technologies and strengthening centres of excellence closer to where patients live.

Commenting on the Day 1 operations of the merged entity, **Dr. Azad Moopen, Executive Chairman, Aster DM Quality Care**, said, "*The coming together of Aster and Quality Care as a single enterprise marks a defining milestone in our journey to build one of India's most trusted and future-ready healthcare institutions. More than the combination of two healthcare networks, it is the convergence of shared values, clinical excellence, deep medical expertise and an unwavering commitment to patient care. Together, we are creating an institution that is stronger, more resilient and better positioned to address the evolving healthcare needs of India.*"

On the strategic priorities for the combined organization, **Mr. Varun Khanna, Managing Director and Group CEO, Aster DM Quality Care** said, "*Aster Quality Care brings together highly complementary institutions, strong clinical ecosystems and teams united by a shared ambition to strengthen healthcare delivery in India. At Aster Quality Care patients and their families will be at the centre of every decision, with digitally enabled solutions and a strong bias for high-quality clinical outcomes. Our immediate focus is disciplined and seamless integration with continuity of patient care. We are committed to ensuring that patients, clinicians, employees and partners experience stability and consistency as we bring together systems, capabilities and best practices across the combined network.*"

The combined platform is expected to unlock significant synergies across clinical collaboration, technology adoption, procurement, digital health and operational excellence. Doctors across the network will increasingly collaborate through shared protocols, multidisciplinary case discussions and centres of excellence, enabling patients to benefit from a broader pool of expertise while receiving consistent standards of care across the network.

With 39 hospitals across 28 cities and over 10,600 beds, Aster DM Quality Care is uniquely positioned to expand access to specialist care, advanced treatment and cutting-edge medical technology across India's tier 2 and tier 3 cities including Nagpur, Aurangabad, Vijayawada, Guntur, Bhubaneswar, Raipur, Nagercoil, Kolhapur, Kannur, Kasaragod, and Kottakkal, reducing the need for patients to travel to metropolitan centres for complex healthcare.

This commitment is a reflection of a vision both organizations have consistently pursued over the years - taking advanced healthcare capabilities to emerging cities. From introducing the first LINAC-based radiation therapy system in Nagercoil to expanding robotic surgery programmes across Raipur, Trivandrum, Kolhapur and soon Guntur and Vijayawada – these investments are not only bringing advanced clinical care closer to patients but also supporting the attraction and retention of high-quality clinical talent in non-metro cities. Building on this foundation, the combined entity will accelerate investments in advanced technologies such as Gamma Knife, stereotactic radiosurgery systems (like ZAP), 10 robotic surgical platforms, and other next generation clinical capabilities, while simultaneously making advanced cancer care more accessible through the addition of 12 LINAC-based radiation therapy systems across tier 2 and tier 3 cities.

The group's combined bed strength is expected to grow to over 15,000 beds over the coming years, helping expand access to affordable care across the country. With more than 45,000 healthcare professionals, the combined entity brings together one of India's most extensive clinical ecosystems, enabling greater collaboration among doctors, nurses and caregivers while strengthening access to high-quality care across the network. As the network grows, the platform is expected to create thousands of additional employment opportunities for doctors, nurses, allied healthcare professionals and support staff, further strengthening the healthcare ecosystem in the communities it serves.

About Aster DM Quality Care Limited*

Aster DM Quality Care Limited is one of India's leading integrated healthcare providers, formed through the merger of Aster DM Healthcare Limited and Quality Care India Limited. The merged entity will bring together four leading healthcare brands - Aster DM, CARE Hospitals, Evercare and KIMSHEALTH, creating a scaled and diversified healthcare platform with a network of 39 hospitals across 28 cities and over 10,600 beds. With a strong presence across South and Central India, the merged entity will deliver comprehensive healthcare services spanning primary, secondary, tertiary and quaternary care, supported by centres of excellence across key specialties including oncology, cardiac sciences, neurosciences, gastro sciences, orthopaedics, nephrology, organ transplantation, mother and child care, and critical care.

Narayana Health Announces India's First Nurse-Led Smart Hospital

Narayana Health has announced the launch of **India's first nurse-led smart hospital** in Bengaluru, introducing a new healthcare delivery model in which specially trained nurses will play a central role in both patient care and hospital administration. The initiative has attracted widespread attention across the healthcare sector.

The hospital aims to combine advanced digital health technologies with nurse-led clinical management, enabling faster patient workflows and more efficient healthcare delivery.

Hospital leadership believes the model will help address workforce shortages while empowering experienced nursing professionals to take on greater leadership responsibilities.

The concept is expected to improve patient satisfaction, reduce administrative bottlenecks, and optimize hospital operations through technology-enabled care pathways.

Healthcare leaders, including industry veterans, have praised the initiative as a significant step toward transforming modern hospital management in India.

If successful, the model could inspire similar nurse-led healthcare facilities across India and other emerging healthcare markets.

HCA Healthcare Revises Outlook Amid Rising Uninsured Patient Volumes

HCA Healthcare, one of the world's largest hospital operators, has revised its annual financial outlook following an increase in uninsured patients and declining elective surgical procedures. The development reflects changing healthcare utilization patterns in the United States.

Despite reporting stronger-than-expected quarterly revenue, the company expects increased uncompensated care costs as more patients lose health insurance coverage.

Hospital executives reported lower inpatient and outpatient surgical volumes compared with previous expectations, affecting profitability.

Industry analysts believe the announcement highlights broader financial challenges facing hospital systems as reimbursement pressures continue to evolve.

Healthcare providers are expected to place greater emphasis on operational efficiency, digital care pathways, and outpatient service expansion to offset financial pressures.

The development is being closely monitored by healthcare investors, insurers, and hospital administrators worldwide.

University of Houston Launches Integrated UH Health Enterprise

The University of Houston has officially launched **UH Health**, bringing together its colleges of medicine, nursing, pharmacy, psychology, optometry, and social work under one integrated healthcare enterprise. The initiative is designed to strengthen interdisciplinary education, research, and patient care.

The new organization will enhance collaboration between clinicians, scientists, and healthcare educators while supporting innovative research programs in cancer, neuroscience, infectious diseases, and population health.

UH Health also plans significant infrastructure expansion, including new research laboratories and clinical education facilities.

Officials believe the integrated model will help prepare the next generation of healthcare professionals while addressing growing workforce shortages.

The initiative is expected to improve access to collaborative clinical research funding and accelerate translation of laboratory discoveries into patient care.

Healthcare experts view integrated academic health systems as increasingly important for advancing precision medicine and multidisciplinary care.

Thailand's Private Hospital Sector Forecast to Rebound Strongly

Thailand's leading private hospital industry is expected to record stronger performance during the second half of 2026 as international medical tourism continues to recover and domestic patient volumes increase. Market analysts have upgraded expectations for several major healthcare providers.

Hospitals are reporting increasing demand across cardiology, oncology, orthopedics, and preventive health screening services.

Growing investments in digital hospitals, robotic surgery, and advanced diagnostic imaging continue to strengthen Thailand's position as a regional healthcare destination.

Medical tourism remains an important growth driver, with hospitals expanding services for international patients seeking high-quality specialized treatment.

Healthcare operators are also increasing investments in AI-assisted diagnostics, telemedicine platforms, and integrated electronic medical record systems.

Analysts expect continued expansion across Southeast Asia's private healthcare market as demand for premium healthcare services grows.

Global Medical Device Companies Intensify Hospital Technology Investments

Leading healthcare technology manufacturers are expanding investments in surgical systems, cardiovascular devices, orthopedic technologies, and digital operating room solutions as hospitals accelerate modernization programs worldwide. Recent market updates indicate sustained momentum in hospital technology adoption.

Hospitals are prioritizing advanced imaging platforms, robotic-assisted surgery, AI-enabled diagnostics, and connected patient monitoring systems.

Healthcare providers continue to modernize operating theatres to improve patient safety, workflow efficiency, and clinical outcomes.

Medical device manufacturers are also increasing investment in minimally invasive treatment technologies and next-generation cardiovascular interventions.

Industry experts expect hospital capital spending on smart healthcare infrastructure to remain robust over the coming years.

The latest developments reinforce the growing importance of digital transformation across hospitals and healthcare systems globally.

Digital Hospitals Continue Rapid Expansion Across Global Healthcare Systems

Healthcare organizations worldwide are accelerating the deployment of artificial intelligence, cloud-connected hospital information systems, predictive analytics, and remote patient monitoring to improve operational efficiency and patient outcomes.

Hospitals are integrating AI-assisted clinical decision support, automated scheduling, and intelligent patient flow management into daily operations.

Remote monitoring technologies are allowing clinicians to supervise patients beyond traditional hospital settings while maintaining continuity of care.

Healthcare administrators report that digital transformation initiatives are reducing waiting times, improving resource utilization, and strengthening clinical decision-making.

The shift toward smart hospitals is also driving greater investment in cybersecurity, interoperable health records, and data-driven healthcare management.

Industry experts believe digital hospitals will play a central role in delivering personalized, efficient, and value-based healthcare over the coming decade, with major healthcare providers continuing to invest in advanced technologies.

Apollo Hospitals Accelerates Expansion with New Multi-Specialty Hospital Investments

Apollo Hospitals Enterprise Ltd. has announced an accelerated expansion strategy aimed at strengthening its presence across Tier-I and Tier-II cities in India. Following strong financial performance, the hospital chain plans significant investments in new multi-specialty hospitals, oncology centres, and digital healthcare infrastructure.

The expansion is designed to meet rising demand for advanced tertiary care, robotic surgery, and specialized clinical services while improving healthcare accessibility.

Apollo's management continues to invest heavily in AI-enabled diagnostics, integrated electronic health records, and digital patient engagement platforms to improve operational efficiency.

Healthcare analysts believe the company's combination of hospital expansion, pharmacy growth, and digital health services positions it for continued long-term growth.

The increasing burden of chronic diseases, ageing populations, and higher healthcare spending continues to drive demand for premium healthcare services across India.

Investors remain optimistic as Apollo continues expanding both its physical hospital network and technology-driven healthcare ecosystem.

IHH Healthcare Strengthens India Growth Strategy Through Capacity Expansion

IHH Healthcare has reaffirmed its long-term commitment to India by announcing additional investments aimed at expanding hospital capacity under its flagship healthcare brands. The company continues to identify India as one of its fastest-growing healthcare markets.

The expansion strategy includes increasing bed capacity, strengthening specialty care programs, and upgrading existing hospitals with advanced medical technologies.

Growing patient volumes, increasing medical tourism, and rising demand for complex procedures continue to support IHH's investment strategy.

The company is also focusing on digital transformation initiatives that improve clinical workflows, patient engagement, and operational efficiency.

Healthcare analysts expect India's private hospital sector to remain one of IHH's strongest growth drivers over the coming years.

The investments reinforce confidence in India's expanding healthcare infrastructure and premium hospital segment.

Ramsay Health Care Focuses on Operational Growth and Private Healthcare Expansion

Australia-based Ramsay Health Care continues strengthening its private hospital business through improved operational efficiency and strategic partnerships with health insurers. Analysts expect the company's hospital operations to benefit from better cost management and growing patient demand.

The company continues investing in modern operating theatres, digital healthcare technologies, and patient experience initiatives.

Private healthcare demand remains strong as hospitals experience increased volumes across orthopaedics, cardiology, oncology, and day-care procedures.

Ramsay is also expanding investments in workforce development, digital health platforms, and hospital modernization projects.

Healthcare experts believe operational excellence will remain critical as hospital operators navigate rising labour and operating costs.

The company's long-term strategy continues to focus on sustainable growth across Australia, Europe, and Asia.

Max Healthcare Emerges as a Top Growth Pick Amid Hospital Infrastructure Boom

Max Healthcare has been identified as one of India's leading hospital growth stories as analysts highlight robust demand for tertiary healthcare services and continued expansion of hospital infrastructure.

The company continues investing in new clinical specialties, advanced surgical technologies, and premium patient care facilities.

Strong occupancy levels, increasing average revenue per occupied bed, and growing demand for complex procedures are supporting revenue growth.

Max Healthcare is also strengthening its oncology, transplant medicine, neuroscience, and cardiovascular care programs across its hospital network.

Industry experts believe India's organized hospital sector remains well positioned to benefit from rising health insurance penetration and increasing healthcare awareness.

Continued investments in digital healthcare and hospital automation are expected to improve operational performance over the coming years.

Bangkok Dusit Medical Services Expands Capital Investments Despite Market Headwinds

Thailand's largest private hospital operator, Bangkok Dusit Medical Services (BDMS), continues investing in hospital modernization and specialty healthcare despite a cautious near-term economic outlook.

The company is expanding investments in advanced diagnostic imaging, minimally invasive surgery, and international patient services.

Medical tourism remains an important long-term growth opportunity as international patient arrivals gradually strengthen.

BDMS is also upgrading digital healthcare systems to improve patient management, operational efficiency, and clinical quality.

Healthcare analysts expect capital investments made today to support future earnings growth as regional healthcare demand continues expanding.

The company remains one of Southeast Asia's largest integrated private healthcare providers.

Brands in Focus: Bangkok Dusit Medical Services (BDMS), Bangkok Hospital, Samitivej Hospital, BNH Hospital.

HCA Healthcare Adjusts Business Strategy Following Market Changes

HCA Healthcare, the largest private hospital operator in the United States, has revised its business outlook while continuing to invest in hospital operations, digital technologies, and patient care infrastructure. The company is adapting its strategy in response to changing reimbursement dynamics and rising uncompensated care costs.

Despite near-term financial pressure, HCA continues expanding investments in surgical services, emergency care, and advanced clinical technologies.

Hospital executives remain focused on improving operational efficiency, workforce productivity, and patient outcomes across their nationwide hospital network.

The company is strengthening digital health initiatives, predictive analytics, and AI-assisted hospital operations to support future growth.

Industry observers note that leading hospital operators continue to prioritize long-term infrastructure investment despite temporary financial headwinds.

HCA's strategic investments reinforce confidence in the long-term demand for high-quality private healthcare services across the United States.

Precision Infusion Redefined: How **AKAS SYRU 1947** Enhances Critical Care Safety

When it comes to **critical care settings**, clinicians make numerous decisions during every shift. Although these decisions are based on knowledge and experience, they also depend on the use of clinically reliable equipment. Infusion pumps may often go unnoticed; however, when administering high-risk medications, they play a vital role in ensuring safe and accurate drug delivery.

Precision Engineered. Clinically Trusted. The **AKAS SYRU 1947** is designed to meet the demanding requirements of critical care and other clinical environments where precise infusion is essential.

Infusion accuracy is the cornerstone of any infusion technology. Precise flow control, combined with continuous monitoring, helps ensure stable and consistent infusion throughout the treatment.

In addition, a comprehensive alarm system and multiple safety features promptly notify healthcare professionals of any changes that may require attention.

Designed with clinicians in mind, the SYRU 1947 combines ease of use with reliable clinical performance**.** Its easy-to-read display, intuitive menu structure, and simplified programming process enable clinicians to set up therapy quickly while reducing the learning curve for new users.

Quiet operation and dependable battery backup help ensure uninterrupted treatment during patient transport or unexpected power failures.

The development of the SYRU 1947 is backed by three decades of expertise in infusion therapy technology.

Since its establishment in 1996, AKAS Medical Equipment has been committed to developing infusion therapy systems that meet the evolving needs of hospitals and healthcare professionals worldwide.
Today, with manufacturing facilities in Trichy and Chennai, and a presence in more than 15 countries and across all states of India, the company continues to invest in engineering excellence, research, and quality-driven manufacturing.

Who We Are
An AS 9001:2000 certified manufacturer specializing in critical care devices, AKAS stands at the forefront of world-class infusion systems and syringe pumps for hospitals and healthcare institutions.

Product Showcase

From its humble beginnings in 1996 in Tiruchirapalli, founded by two visionary engineers, AKAS has grown into one of India's leading infusion pump manufacturers.

Today, with state-of-the-art manufacturing facilities in Tiruchirapalli and Chennai, and a presence in 15+ countries, AKAS continues to expand its global footprint.

What truly sets AKAS apart is its multidisciplinary team—a powerful collaboration of engineers, R&D specialists, and medical professionals—driving innovation that meets the highest standards of performance, safety, and reliability.
Experience the Future of Infusion Technology
https://www.akasinfusions.com/
AKAS Medical Equipment
SP127, 1st Main Road,
Ambattur Industrial Estate,
Chennai – 600058
+91-98403 79116
sales@akasinfusions.com

Labcorp Launches RNA-Based At-Home Colorectal Cancer Test Nationwide

The test detect signs of colorectal cancer and precancerous growths using a home collection kit.

Labcorp announced the nationwide availability of ColoSense, an RNA-based at-home screening test for colorectal cancer approved by the Food and Drug Administration (FDA).

Offered through a commercial collaboration with test developer Geneoscopy, the test expands Labcorp's range of colorectal cancer screening solutions. The test is now covered for eligible Medicare and Medicare Advantage beneficiaries following an update to the National Coverage Determination by the Centers for Medicare & Medicaid Services in June, with additional commercial coverage also available.

ColoSense uses RNA-based technology to detect biomarkers associated with colorectal cancer and advanced adenomas, which are precancerous changes that may be an early indication of disease. The test aligns with stool-based RNA screening approaches recognized in the American Cancer Society colorectal cancer screening guidelines and is included as a recommended screening option in the National Comprehensive Cancer Network guidelines.

"Labcorp is focused on improving colorectal cancer screening rates by offering at-home options consumers are more likely to complete," says Brian Caveney, chief medical and scientific officer at Labcorp, in a release. "With ColoSense now available nationwide, we're expanding access to an FDA-approved screening option that delivers advanced science and a more streamlined, easier-to-use collection experience."

The test is available through healthcare providers for adults aged 45 to 85 at average risk. It is not intended for individuals with a history of colorectal cancer or certain high-risk conditions. In clinical performance evaluations, the test demonstrated 93% sensitivity for colorectal cancer in average-risk individuals and achieved 100% sensitivity for stage I colorectal cancer, according to the company.

"ColoSense reflects years of scientific innovation focused on improving how we screen for colorectal cancer at home," says Matt Sargent, chief commercial officer at Geneoscopy, in a release.

The collection kit is delivered directly to the consumer's home and features a design that eliminates the need to separate or mix the stool sample. Labcorp research indicates that among users of at-home screening tests, 41% were uncomfortable preparing the sample, and 34% said the process felt messy.

Geneoscopy provides patient navigation support to help individuals understand their results and follow recommended next steps, including a colonoscopy after a positive result. Labcorp notes that ColoSense is a screening test and does not replace diagnostic colonoscopy.

LigoLab and MarginLogic Health AI Partner to Automate Laboratory Data Entry

The integration uses artificial intelligence to capture data from paper requisitions, aiming to reduce manual entry and speed up laboratory processing.

LigoLab and MarginLogic Health AI have announced a marketplace agreement to integrate artificial intelligence-powered optical character recognition (OCR) technology into laboratory workflows. The partnership allows clinical laboratories, reference labs, and pathology groups to automate requisition intake and accessioning within LigoLab's laboratory information system (LIS) and revenue cycle management informatics platform.

The integrated solution uses artificial intelligence to capture, interpret, and validate data from requisitions, physician orders, insurance cards, and patient demographics. Validated orders are then transmitted into the LigoLab platform. According to the companies, the integration results in faster accessioning, fewer manual keystrokes, and more efficient laboratory operations.

"Requisition intake and accessioning is where laboratories lose time and accuracy before a specimen even reaches the LIS," says Jenny Bull, LigoLab's success director, in a release.

"Pairing MarginLogic Health AI's OCR with our platform lets high-confidence orders flow straight through, so staff can focus on the exceptions instead of retyping what should already be structured data."

Unlike traditional OCR solutions that convert images into text, the MarginLogic Health AI technology uses contextual artificial intelligence to understand clinical documents. The system recognizes handwritten and printed requisitions, validates extracted information, and flags ambiguous fields for human review. High-confidence requisitions are processed with minimal manual intervention, while lower-confidence fields are routed for review to ensure accuracy.

"Laboratories shouldn't lose hours retyping what a document already contains. Our AI reads a clinical requisition the way an experienced accessioner would — interpreting context, validating what it captures, and flagging only the fields that genuinely need a human," says Ammar Darkazanli, CEO and president of MarginLogic Health AI, in a release.

The partnership is intended for laboratories that receive volumes of faxed, handwritten, or paper requisitions. Even organizations with electronic ordering often process non-integrated orders that require manual entry.

Beyond operations, the partnership aims to improve financial performance by increasing demographic accuracy and reducing transcription errors, which can minimize claim issues and denials.

The integration complements existing laboratory interfaces. Electronic orders from provider electronic health records continue to flow through established connections, while the AI technology automates the processing of paper-based and non-integrated requisitions.

MarginLogic Health AI solutions are currently available to LigoLab customers.

Siemens Healthineers Launches New Hematology Analyzer for US Laboratories

The Atellica HEMA 580 is designed for mid- to high-volume labs to automate testing workflows and reduce preanalytical variability.

Siemens Healthineers has introduced the Atellica HEMA 580 Analyzer to the US market, a system designed for mid- to high-volume laboratories to address workflow inefficiencies and staffing pressures.

According to a press release from Siemens Healthineers, nearly 500 million complete blood counts are performed annually, and the new analyzer aims to streamline the testing process to improve clinical decision-making.

The system is intended to produce reliable results even in environments facing high volume and understaffing.

"Hematology testing acts as a clinical GPS, helping to inform early patient care decisions," says Michele Zwickl, head of laboratory solutions for diagnostics at Siemens Healthineers North America, in a release. "Our sustainable, scalable solution helps busy labs avoid workflow bottlenecks."

The analyzer uses proprietary 360-degree continuous sample mixing to keep samples in motion before analysis, which helps reduce preanalytical variability without requiring manual steps, according to the company. The system can produce results in 30 seconds, while advanced platelet and reticulocyte parameters are available within 60 seconds.

To support consistency across different staff experience levels, the Atellica HEMA 580 automatically releases normal results to the **laboratory information system**. Abnormal samples are held for review, and the system provides rule-based guidance to help staff follow approved laboratory protocols, according to the press release.

The technology also integrates with the **Scopio X100 and Scopio X100HT** imaging platforms, which provide high-resolution digital morphology for peripheral blood smears using artificial intelligence. Bi-directional connectivity with the Atellica Data Manager software allows for remote review of complete blood count results and differentials within a unified digital workspace.

"Upgrading to the Atellica HEMA 580 analyzer has transformed our workflow," says Apostolia Barmpoudi, senior biomedical scientist at St James' University Hospital, in a release. "Interfacing [the analyzers] with **total lab automation** gives us the flexibility we need, while the speed and consistent uptime keep our lab running at peak efficiency."

The system also includes streamlined reagent management and reduced daily maintenance to support predictable costs and uptime, according to Siemens Healthineers. The analyzer can also be connected to multidisciplinary automation tracks to help laboratories scale operations as testing demands change.

Spear Bio to Release New Alzheimer's Disease Tests and Automated Instrument Platform

The company is introducing blood-based assays for tau biomarkers and a platform to automate laboratory workflows.

Spear Bio announced it will unveil new immunoassays and a **fully automated instrument platform** at the **Alzheimer's Association International Conference** 2026 in London, UK.

The launches include a singleplex immunoassay for eMTBR-Tau and an assay for **pTau 217** that measures the biomarker across both venous and capillary blood. These tools are designed to help researchers investigate amyloid-associated tau phosphorylation and tau tangle pathology using ultra-low sample volumes, according to the company.

Assay Technology and Performance

The new assays are built on Successive Proximity Extension Amplification Reaction technology. This method combines attomolar sensitivity with a wash-free workflow and requires 1 μL of diluted plasma. The technology allows scientists to preserve biospecimens while generating biomarker data for **Alzheimer's disease**, neurodegeneration, and preclinical research, according to Spear Bio.

The eMTBR-Tau immunoassay is designed as a standalone test that provides a quantitative approach to measuring biology associated with tau tangles. The pTau 217 assay complements this by enabling consistent measurement in different blood types to support the study of tau phosphorylation.

Automated Workflow Integration

The new instrument platform is designed to automate the company's workflows from the initial sample to a quantitative polymerase chain reaction-ready plate. By reducing manual handling, the system supports more consistent execution of biomarker assays and is intended to help laboratories scale and integrate the technology into research and clinical development.

"Our focus is on building innovations that help researchers answer questions that were previously difficult to address with conventional protein biomarker tools," says Feng Xuan, founder and CEO of Spear Bio, in a release. "As the field advances from biomarker discovery toward broader validation, vigorously verified assays become essential to generating reliable, reproducible insights."

According to Xuan, the platform provides researchers with a way to measure complex Alzheimer's disease biology and supports the next stage of neurodegenerative disease research.

In addition to the product launches, the company plans to present data regarding synucleinopathy and TDP-43 proteinopathy at the conference. Presentations will include discussions on using the assays for amyloid pathology discrimination and studies in mouse models.

Bio-Rad Releases New Quality Control Kits for Cell and Gene Therapy

The droplet digital PCR kits, for quality control in cell and gene therapy manufacturing, offer validated workflows for mycoplasma detection, capsid analysis, and residual DNA quantification.

Bio-Rad Laboratories announced the launch of its Vericheck **droplet digital PCR** (ddPCR) kit portfolio, which is designed for quality control workflows in cell and gene therapy development and other biopharmaceutical applications.

The kits are compatible with the company's QX700 System. The portfolio includes kits for mycoplasma detection, empty-full capsid, replication-competent lentivirus, and residual DNA quantification for Chinese hamster ovary and E coli.

The QX700 platform enables seven-color multiplexing and has the capacity to process up to 384 reactions in approximately two and a half hours, according to Bio-Rad. The system requires minimal input volume and features continuous loading capability and software for data interpretation. By combining the platform with the Vericheck kits, researchers can generate results for product development, product safety, and quality.
In the development and manufacturing of advanced therapeutics, quality control testing is used to ensure the safety and effectiveness of the product. The new kits provide validated workflows intended to improve confidence in vector characterization and contamination detection, including replication-competent virus testing, and residual host cell DNA quantification.

"The expansion of our range of Vericheck ddPCR Kits offers validated workflows with unmatched precision and sensitivity, combined with the power of the QX700 platform, enabling scalable, streamlined workflows and faster time to actionable results," says Stephen Kulisch, vice president of marketing of digital biology group at Bio-Rad, in a release.

Thermo Fisher Scientific Launches New Quality Assurance Software



The digital tool is designed to simplify quality control workflows and speed up decision-making in clinical laboratories.

Thermo Fisher Scientific has introduced LabLink 360 Quality Assurance software, a new digital solution intended to help clinical laboratories simplify quality control (QC) workflows and accelerate decision-making. The software aims to improve visibility into QC performance and help staff proactively manage operations.

According to the 2025 Westgard Global QC Practices Survey, one in three laboratories experience out-of-control QC events every day, and 75% of labs repeat controls during troubleshooting, which increases workload and delays results, according to a release from Thermo Fisher Scientific.

Automating Quality Control Review

LabLink 360 consolidates QC data and automates routine review steps. The software uses data visualizations and a centralized dashboard to bring QC metrics into a single view.

The platform also includes built-in **peer group benchmarking**, which allows for real-time comparison directly within daily workflows. For organizations with multiple locations, the software provides oversight across multi-site and referral networks. These features allow issues that previously required manual cross-referencing to be identified, prioritized, and resolved faster, according to the company.

"Clinical laboratories are being asked to do more with less," says Anuj Dhingra, vice president and general manager, niche diagnostics, clinical diagnostics division, Thermo Fisher Scientific, in a release.

"LabLink 360 extends our MAS portfolio into the workflow itself, giving laboratory staff the data and automation they need to focus on what actually requires their expertise."

Integration with Automation Workflows

The software is designed to work with the MAS Quality Controls portfolio. It adds a workflow and analytics layer that supports integration with MAS Max Load & Go Automation Workflows, which are used in high-volume and automated testing environments.

Global availability of the software will be phased according to local regulatory and market requirements, according to the company.

Subscribe now !!

microbiozhealth.com

support@microbiozindia.com

TECHNOCARE MEDISYSTEMS

TRUSTED COMPANY IN **MEDICAL INNOVATION** SINCE 2001

We proudly offer the lowest prices in India, guaranteed—without compromising on quality. Our mission is simple:

"TO PROVIDE QUALITY MATERIAL AND THE BEST SERVICE."

For orders and inquiries, contact:

POOJA DHADUK

+91 95374 17749

Multipara Monitor

Multipara Monitor

SYRINGE INFUSION PUMP

SYRINGE INFUSION PUMP

ECG MACHINE-TM-3E

ECG MACHINE-TM-1201

ECG MACHINE TM-302

ECG MACHINE TM-12E

FETAL MONITOR

PHOTOTHERAPHY & BABY WARMER & BABY WEIGHT SCALE

VAIN FINDER

MONITOR STAND AND TROLLEY

JAUNDICE METER

PULSE OXIMETER

PULSE OXIMETER

RESPIRATORY PRODUCTS

BIPAP

FOGGER MACHINE AND FUMIGATOR

DEFIBRILLATOR AND AED

AED

- DVT PUMP
- FETAL DOPPLER
- 3CH, 12CH HOLTER RECORDER
- AMBULATORY BP MONITOR
- SPIROMETER
- video laryngoscpes
- PATIENT WARMER WITH BLANCKETS AND TROLLEY
- BLOOD/FLUID WARMER
- VIDEO LARYNGOSCOPE
- VENTILATOR
- ORTHO DRIL
- OXYGEN CONCERNTRATOR
- CAUTERY MACHINE
- DIGITAL TOURNIQUET
- EMERGENCY AMBULANCE TROLLEY
- COMPITABLE SPO2 SENSOR
- FETAL MONITOR
- BIPAP
- HD/NON-HD VIDEO COLPOSCOPE
- INTENSIVE CARE SERVO WARMER
- DIGITAL BABY SCALE
- SUCTION MACHINE
- ETCO2 MONITOR
- FOGGER MACHINE
- FUMIGATOR
- STANDS AND TROLLEY

Address:-C-1310/1311, New Bombay Market, Umarwada, Surat-395010
Email:technocare9@Gmail.Com

PUBLISHED ON: 25th July 2026 RNI NUMBER: UPENG/2017/73675

AKAS® INFUSIONS

PRECISION DELIVERED

At AKAS Infusions, we believe that accuracy and reliability define exceptional patient care. Our wide range of infusion solutions is designed to meet diverse medical needs with seamless delivery and advanced technology.

Hello
Helps to prevent Deep Vein Thrombosis

AKAS® INFUSIONS

WARMJET
Blood and Fluid Warmer

Made in India. Made for the World.

AKAS Medical Equipment,
SP127, 1st Main road, Ambattur Industrial Estate, Chennai 600058

+91-98403 79116
sales@akasinfusions.com
www.akasinfusions.com

CE 1023